Compile Data Set for Download or QSAR
Report error Found 162 of affinity data for UniProtKB/TrEMBL: Q96PD4
TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617543(US20230286943, Example 11)
Affinity DataIC50: 20nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617538(US20230286943, Example 6)
Affinity DataIC50: 31.6nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617626(US20230286943, Example 94)
Affinity DataIC50: 31.6nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617633(US20230286943, Example 101)
Affinity DataIC50: 31.6nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617671(US20230286943, Example 139)
Affinity DataIC50: 31.6nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617573(US20230286943, Example 41)
Affinity DataIC50: 39.8nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617574(US20230286943, Example 42)
Affinity DataIC50: 39.8nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617575(US20230286943, Example 43)
Affinity DataIC50: 39.8nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617578(US20230286943, Example 46)
Affinity DataIC50: 39.8nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617627(US20230286943, Example 95)
Affinity DataIC50: 39.8nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617642(US20230286943, Example 110)
Affinity DataIC50: 39.8nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617544(US20230286943, Example 12)
Affinity DataIC50: 50.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617547(US20230286943, Example 15)
Affinity DataIC50: 50.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617577(US20230286943, Example 45)
Affinity DataIC50: 50.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617534(US20230286943, Example 2)
Affinity DataIC50: 63.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617535(US20230286943, Example 3)
Affinity DataIC50: 63.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617541(US20230286943, Example 9)
Affinity DataIC50: 63.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617567(US20230286943, Example 35)
Affinity DataIC50: 63.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617582(US20230286943, Example 50)
Affinity DataIC50: 63.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617587(US20230286943, Example 55)
Affinity DataIC50: 63.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617614(US20230286943, Example 82)
Affinity DataIC50: 63.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617615(US20230286943, Example 83)
Affinity DataIC50: 63.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617659(US20230286943, Example 127)
Affinity DataIC50: 63.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617661(US20230286943, Example 129)
Affinity DataIC50: 63.1nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617533(US20230286943, Example 1)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617548(US20230286943, Example 16)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617555(US20230286943, Example 23)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617561(US20230286943, Example 29)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617562(US20230286943, Example 30)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617583(US20230286943, Example 51)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617600(US20230286943, Example 68)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617622(US20230286943, Example 90)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617629(US20230286943, Example 97)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617652(US20230286943, Example 120)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617654(US20230286943, Example 122)
Affinity DataIC50: 79.4nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617546(US20230286943, Example 14)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617557(US20230286943, Example 25)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617560(US20230286943, Example 28)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617563(US20230286943, Example 31)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617606(US20230286943, Example 74)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617610(US20230286943, Example 78)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617620(US20230286943, Example 88)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617639(US20230286943, Example 107)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617650(US20230286943, Example 118)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617663(US20230286943, Example 131)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617664(US20230286943, Example 132)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617545(US20230286943, Example 13)
Affinity DataIC50: 126nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617554(US20230286943, Example 22)
Affinity DataIC50: 126nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617559(US20230286943, Example 27)
Affinity DataIC50: 126nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetInterleukin-17F(Human)
Sanofi

US Patent
LigandPNGBDBM617566(US20230286943, Example 34)
Affinity DataIC50: 126nMAssay Description:The ability of the compounds to block binding of IL-17A to its receptor, IL-17RA, was analysed in a competition assay using AlphaLISA technology (Per...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 162 total ) | Next | Last >>
Jump to: